AD Therapeutics Studies

Enrollment Status
Study Type
Age Range
Cognitive Status
, ,
The AlzMatch Study tests whether a single blood test, collected at community-based laboratories, can help speed clinical trial enrollment by identifying people most likely to have amyloid in the brain.  Brain amyloid is a protein that builds up in people who may go on to have memory problems because of Alzheimer’s disease.  Many studies are looking for individuals who have an increased likelihood of having amyloid, and the AlzMatch Study seeks to simplify the screening process for these studies using a blood test.  AlzMatch is inviting participants who are registered in the Alzheimer Prevention Trials (APT) Webstudy and are over 50 years of age, with no diagnosis of dementia. After consent, the primary measures are engagement of eligible participants and collection of blood samples. All participants will be informed of their eligibility to be screened for a clinical study. If eligible and agree to referral, participants will be connected to a local research site for in-person evaluation.  Learn more about the APT Webstudy at:   
, ,
Those identified to have a potential increased risk for memory loss caused by Alzheimer’s disease, will be referred from the APT Webstudy (above) to the Trial Ready Cohort for the Prevention of Alzheimer’s Dementia (TRC-PAD) in-person study. The purpose of TRC-PAD is to find as many people as possible (also called a “cohort”) who are interested in participating in clinical trials aimed at discovering treatments that will reduce the risk of developing Alzheimer’s dementia. TRC-PAD will help researchers enroll participants into these trials quickly to allow new treatments to be discovered as soon as possible. Participants do not have to participate in the TRC-PAD study in order to participate in the online APT Webstudy.
, ,
The Trial-Ready Cohort- Down Syndrome (TRC-DS) aims to enroll 120 non-demented adults (ages 25-55) with Down syndrome (DS) into a trial ready cohort (TRC). Participants enrolled in the TRC-DS will undergo longitudinal cognitive and clinical assessment, genetic and biomarker testing, as well as imaging and biospecimen collection. Using these outcome measures, researchers will analyze the relationships between cognitive measures and biomarkers of Alzheimer’s disease (AD) to identify endpoints for AD clinical trials in DS that best reflect disease progression.
, , ,
The LEADS study – or the Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS) explores the development of early-onset Alzheimer’s disease and how it compares to the more common late-onset Alzheimer’s disease. Better understanding of this form of the disease may ultimately lead to more effective treatments. LEADS is a 2-year observational study designed to enroll 500 participants. Researchers are also recruiting cognitively normal volunteers for a 1-year comparison.
, ,
If you are 50 years of age or older, you can monitor your own cognitive health by participating in the Alzheimer Prevention Trials (APT) Webstudy. The APT Webstudy is designed to identify people who may have an increased risk for developing Alzheimer’s disease, using the latest technology to monitor their cognitive performance through regular online memory testing. Volunteers of the APT Webstudy participate at their convenience, anywhere they have access to the internet.
, ,
AHEAD Study is a global multicenter clinical trial aimed at preventing memory loss due to Alzheimer’s disease, designed and conducted by the Alzheimer’s Clinical Trials Consortium (ACTC) in collaboration with Eisai. Funding is through a public-private partnership with National Institute on Aging (NIH), Eisai, and several philanthropic organizations. It is led by three academic principal investigators: Dr. Paul Aisen from University of Southern California, and Drs. Reisa Sperling and Keith Johnson from Brigham and Women’s Hospital and Massachusetts General Hospital, Harvard Medical School.